304 related articles for article (PubMed ID: 10640577)
1. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes.
Crosasso P; Ceruti M; Brusa P; Arpicco S; Dosio F; Cattel L
J Control Release; 2000 Jan; 63(1-2):19-30. PubMed ID: 10640577
[TBL] [Abstract][Full Text] [Related]
2. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel.
Ceruti M; Crosasso P; Brusa P; Arpicco S; Dosio F; Cattel L
J Control Release; 2000 Jan; 63(1-2):141-53. PubMed ID: 10640588
[TBL] [Abstract][Full Text] [Related]
3. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation.
Yang T; Cui FD; Choi MK; Cho JW; Chung SJ; Shim CK; Kim DD
Int J Pharm; 2007 Jun; 338(1-2):317-26. PubMed ID: 17368984
[TBL] [Abstract][Full Text] [Related]
4. Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo.
Cai L; Wang X; Wang W; Qiu N; Wen J; Duan X; Li X; Chen X; Yang L; Qian Z; Wei Y; Chen L
Int J Nanomedicine; 2012; 7():4499-510. PubMed ID: 22923988
[TBL] [Abstract][Full Text] [Related]
5. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel.
Immordino ML; Brusa P; Arpicco S; Stella B; Dosio F; Cattel L
J Control Release; 2003 Sep; 91(3):417-29. PubMed ID: 12932719
[TBL] [Abstract][Full Text] [Related]
6. Preparation of pegylated nano-liposomal formulation containing SN-38: In vitro characterization and in vivo biodistribution in mice.
Atyabi F; Farkhondehfai A; Esmaeili F; Dinarvand R
Acta Pharm; 2009 Jun; 59(2):133-44. PubMed ID: 19564139
[TBL] [Abstract][Full Text] [Related]
7. Novel taxol formulations: preparation and characterization of taxol-containing liposomes.
Sharma A; Straubinger RM
Pharm Res; 1994 Jun; 11(6):889-96. PubMed ID: 7937531
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel-loaded stealth liposomes: Development, characterization, pharmacokinetics, and biodistribution.
Xu Y; Meng H
Artif Cells Nanomed Biotechnol; 2016; 44(1):350-5. PubMed ID: 25162671
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel.
Chen DB; Yang TZ; Lu WL; Zhang Q
Chem Pharm Bull (Tokyo); 2001 Nov; 49(11):1444-7. PubMed ID: 11724235
[TBL] [Abstract][Full Text] [Related]
10. Preparation, Characterization, and Pharmacokinetic Study of a Novel Long-Acting Targeted Paclitaxel Liposome with Antitumor Activity.
Han B; Yang Y; Chen J; Tang H; Sun Y; Zhang Z; Wang Z; Li Y; Li Y; Luan X; Li Q; Ren Z; Zhou X; Cong D; Liu Z; Meng Q; Sun F; Pei J
Int J Nanomedicine; 2020; 15():553-571. PubMed ID: 32158208
[TBL] [Abstract][Full Text] [Related]
11. Improved Antitumor Activity of Novel Redox-Responsive Paclitaxel-Encapsulated Liposomes Based on Disulfide Phosphatidylcholine.
Du Y; Wang Z; Wang T; He W; Zhou W; Li M; Yao C; Li X
Mol Pharm; 2020 Jan; 17(1):262-273. PubMed ID: 31747284
[TBL] [Abstract][Full Text] [Related]
12. Preparation and evaluation of paclitaxel-containing liposomes.
Holvoet C; Vander Heyden Y; Lories G; Plaizier-Vercammen J
Pharmazie; 2007 Feb; 62(2):126-32. PubMed ID: 17341033
[TBL] [Abstract][Full Text] [Related]
13. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
Dadashzadeh S; Vali AM; Rezaie M
Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
[TBL] [Abstract][Full Text] [Related]
14. Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo.
Lu J; Chuan X; Zhang H; Dai W; Wang X; Wang X; Zhang Q
Int J Pharm; 2014 Aug; 471(1-2):525-35. PubMed ID: 24858391
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel loaded PEG(5000)-DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation.
Gill KK; Nazzal S; Kaddoumi A
Eur J Pharm Biopharm; 2011 Oct; 79(2):276-84. PubMed ID: 21575719
[TBL] [Abstract][Full Text] [Related]
16. Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo.
Biswas S; Dodwadkar NS; Deshpande PP; Torchilin VP
J Control Release; 2012 May; 159(3):393-402. PubMed ID: 22286008
[TBL] [Abstract][Full Text] [Related]
17. Liposome formulation of paclitaxel with enhanced solubility and stability.
Yang T; Cui FD; Choi MK; Lin H; Chung SJ; Shim CK; Kim DD
Drug Deliv; 2007 Jul; 14(5):301-8. PubMed ID: 17613018
[TBL] [Abstract][Full Text] [Related]
18. Novel Taxol formulations: Taxol-containing liposomes.
Straubinger RM; Sharma A; Murray M; Mayhew E
J Natl Cancer Inst Monogr; 1993; (15):69-78. PubMed ID: 7912532
[TBL] [Abstract][Full Text] [Related]
19. Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: in vitro and in vivo studies.
Zhang JQ; Zhang ZR; Yang H; Tan QY; Qin SR; Qiu XL
Pharm Res; 2005 Apr; 22(4):573-83. PubMed ID: 15846465
[TBL] [Abstract][Full Text] [Related]
20. Serum-stable, long-circulating paclitaxel-loaded colloidal carriers decorated with a new amphiphilic PEG derivative.
Basile L; Passirani C; Huynh NT; Béjaud J; Benoit JP; Puglisi G; Pignatello R
Int J Pharm; 2012 Apr; 426(1-2):231-238. PubMed ID: 22306040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
